Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare Psychedelics

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Post by shadowcatcheron Apr 13, 2012 4:34pm

276 Views

Post# 19792459

AGAIN - More inside buying

https://www.canadianinsider.com/node/7?menu_tickersearch=BRD+%7C+Brigus+Gold

Filing
DateTransaction
DateInsider NameOwnership
TypeSecuritiesNature of transaction# or value acquired or disposed ofUnit
PriceApr 12/12Apr 12/12Dawe, Wade K.Direct OwnershipCommon Shares10 - Acquisition in the public market50,000
.790
Apr 11/12Apr 11/12Burgess, HarryDirect OwnershipCommon Shares10 - Acquisition in the public market10,000
.740
Apr 11/12Apr 11/12Legatto, JonDirect OwnershipCommon Shares10 - Acquisition in the public market6,900
.720
Apr 11/12Apr 11/12Legatto, JonIndirect OwnershipCommon Shares10 - Acquisition in the public market7,360
.720
Apr 3/12Apr 2/12Gill, Derrick EdwinDirect OwnershipCommon Shares10 - Acquisition in the public market20,000
.770
Apr 3/12Apr 2/12Dawe, Wade K.Direct OwnershipCommon Shares10 - Acquisition in the public market50,000
.780
Apr 2/12Mar 30/12Nicholson, Jennifer LynnControl or DirectionCommon Shares10 - Acquisition in the public market12,500
.788
Apr 2/12Mar 30/12Nicholson, Jennifer LynnControl or DirectionCommon Shares10 - Acquisition in the public market12,500
.789
Apr 2/12Mar 30/12Hatfield, Dana MurrayDirect OwnershipCommon Shares10 - Acquisition in the public market10,000
.800
Apr 2/12Mar 30/12Hatfield, Dana MurrayDirect OwnershipCommon Shares10 - Acquisition in the public market20,000
.770
Sign up for an account or login above to see all SEDI filings within the past 6 months.